The US Food and Drug Administration (FDA) has approved Mandos LLC's adrabetadex (Lembaz), the first treatment shown to reduce mortality risk in Niemann-Pick disease type C (NPC). The approval covers adults and children weighing at least 7 kg whose neurological symptoms began before age 6, a population with infantile-onset NPC.
NPC is an inherited lysosomal storage disorder in which impaired intracellular cholesterol trafficking causes lipid accumulation and progressive neurological deterioration. According to the FDA, 2 previously approved treatments have not demonstrated a mortality benefit. Adrabetadex, developed by Mandos, a subsidiary of Beren Therapeutics, is a cyclodextrin-based therapy that binds cholesterol and helps move it out of lysosomes, although the prescribing information notes that the mechanism underlying the observed survival benefit has not been fully characterized.
The decision was supported by an integrated survival analysis of 36 adrabetadex-treated patients from 3 clinical trials and an expanded access program, compared with matched external controls from a natural history study. The nonrandomized analysis included patients whose neurological symptoms began before age 6 and accounted for disease subtype, age at neurological onset, and baseline miglustat use when matching patients.
According to the prescribing information, median overall survival was 102 months (8.5 years) with adrabetadex vs 59 months (4.9 years) in the matched external-control group. The relative risk of death was reduced by 55%. Deaths occurred in 12 of 36 treated patients vs an estimated 24 of 36 weighted external controls. Longer survival was observed regardless of baseline miglustat use.
Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss. The label requires comprehensive audiological evaluation before treatment and repeated assessments during dose escalation, with subsequent dose adjustments based on hearing findings. Other common adverse reactions include ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.
Dosing instructions specify intrathecal administration every 2 weeks by, or under the supervision of, a clinician experienced in lumbar punctures. Starting doses range from 100 to 400 mg based on age, with upward titration based on tolerability and weight-dependent maximum doses of 600 or 900 mg. The label also advises considering dose reductions for severe ataxia or fatigue.
